IN THE KIN ES PATENT AND TRADEMARK OFFICE

re Application of:

Rochus JONAS et al.

Serial No.: 10/018,484

Group Art Unit: 1614

Filed: May 10, 2002

Examiner: Unassigned

For: THIENOPYRIMIDINES AS PHOSPHODIESTERASE INHIBITORS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Assistant Commissioner for Patents Washington, D. C. 20231

RECEIVED

JUL 2 9 2002

Sir:

TECH CENTER 1600/2900

CITED	<u>OMATERIALS</u>						
Applic	ant(s) hereby disclose the information listed in the attached form PTO-1449.						
	Copies of materials listed but not attached were cited in parent application Serial No; see 37 C.F.R. § 1.98(d).						
⊠	Copies of materials listed but not attached were cited in an International Search Report dated <u>September 13, 2000</u> ; receipt of the International Search Report and copies of references was confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed <u>June 7, 2002</u> .						
<u>ADDI</u>	TIONAL INFORMATION .						
LANG	<u>UAGE</u>						
	All listed materials are in the English language; see 37 C.F.R. § 1.98.						
	Non-English language references:						
	\square The reference(s): in the English-language is (are) indicated by commercial data bases to correspond to the reference(s): , respectively.						
	\square (An) English-language translation(s) of the references: is (are) provided.						
	☐ A commercial English-language abstract of reference(s) is (are) provided.						

An English-language search report or an equivalent paper from a foreign patent office translated into English in pertinent part in connection with a counterpart foreign application, is provided indicating the relevance of the cited reference(s).

FEES

A	140 100	is required for this information Disclosure Statement occause.					
	This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;						
	□ a first a	This Information Disclosure Statement is being filed before the mailing of action on the merits;					
	notice	This Information Disclosure Statement is being filed after a first action on rits but before the mailing date of any of a final action under § 1.113, a of allowance under § 1.311, or an action that closes prosecution in the ation, and is accompanied by a certification below.					
		This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(i).					
	A fee i	s required for this Information Disclosure Statement:					
	This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in §1.17(p).						
	prosect	This Information Disclosure Statement is being filed after the mailing date all rejection or a notice of allowance under § 1.311 or an action that closes ution, but before the payment of the issue fee, and is accompanied by the forth in § 1.17(p) and a certification below.					
<u>CERT</u>	IFICAT	ION					
	Each item of information contained in this Information Disclosure Statement wa cited in a communication from a foreign patent office in a counterpart foreig application not more than three months prior to the filing of this statement.						
	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, no such item was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.						

DEPOSIT ACCOUNT

If a fee is due, attached is a check in the amount of \$\sum_\$. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza I 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-2333

Date: July 25, 2002

AJZ:jr

Please type a plus sign (+) inside this box	+	
---	--------------	--

ute for form 1449A/PTO

Sheet

PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

FORMATION DISCLOSURE STATEMENT BY APPLICANT

of

 Complete if Known

 Application Number
 10/018,484

 Filing Date
 May 10, 2002

 First Named Inventor
 Rochus JONAS et al.

 Group Art Unit
 1614

(use as many sheets as necessary)

Examiner Name Unassigned
Attorney Docket Number MERCK-2333

2 9 2002

Examiner Initials* Cite No. Number Kind Code (if known)

Name of Patentee or Applicant of Cited Document MMA-DD-YYYY

Date of Publication of Cited Document Passages or Relevant Figures Appear

1600/2900

				FOREIG	N PATENT DOCU	MENTS		
Examiner	Cite No.1	Foreign Patent Document		Name of Patentee or Applicant of	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant		
Initials*		Office ³		ind Code⁵ if known)	Cited Document	MM-DD-YYYY	Passages or Relevant Figures Appear	T ₆
		DE	198 19023	Α		11/04/1999		
		DE	196 44228	Α		04/30/1998		
		<u> </u>						
		 						
		ļ						
	 	 	 					

	Examiner Signature		Date Considered	
--	-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.